Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AEMD is going through a reverse split in preparation for uplisting to NASDAQ. Very high potential biotech company. The CEO stated earlier this year that uplisting in 2015 was a goal and the process just got started.
The RS will put the share price within range for NASDAQ uplisting, and the reduced share count should reduce volatility. This is good news in my opinion.
http://www.exosomesciences.com/AboutESI.aspx
"Exosome Sciences, Inc. (ESI), a majority owned subsidiary of Aethlon Medical, Inc., creates diagnostic tools to detect and quantify the presence of exosomes in blood and other fluids. Our lead product, the Enzyme Linked Lectin Specific Assay (ELLSA) has been validated to identify the presence of exosomes underlying the human immunodeficiency virus (HIV), tuberculosis (TB), and various forms of cancers, including ovarian, melanoma, breast, lymphoma, and colorectal."
http://biz.yahoo.com/e/150316/aemd8-k.html
DARPA modified milestones to help transition the HP from research to production. My take on this is that DARPA is basically saying that they are convinced it works. They don't need to see more experiments, they want it available commercially.
Applications of the HP beyond viral capture rely on exosome research. Look at Aethlon's website under product pipeline where it talks about HER2osome and ELLSA. Also on ESI's web site under the ELLSA Assay is states:
"To support the therapeutic advances of Aethlon Medical to eliminate disease-enhancing exosomes from circulation, researchers needed to create a highly sensitive diagnostic tool that was able to isolate a broad-spectrum of disease-related exosomes. The result was ELLSA..."
My interpretation of the above statement is that the HP is very much dependent on the research and intellectual property of ESI.
I disagree with selling ESI for a few reasons. One, my understanding is that the intellectual property behind ESI is critical to Aethlon's product pipeline as well. They can't give someone else control of that. Second, selling ESI would not take away the need for a reverse split at this time. It would only provide some funding for trials. The need for the RS is primarily that they have 300 million outstanding shares, so $4.00 per share would put the market cap over a billion. I don't think a market cap that high is justified at this point, and they want/need a higher share price for NASDAQ uplisting and more institutional investing.
I can understand that you would be upset if you bought during the ebola pump. Based on things I saw posted there was a pump and dump run by third parties. That's what stock traders do. But this is a clinical stage company moving in the right direction. They have a ways to go before they will be making sales, but the potential is high. And if they continue cleaning up the balance sheet and share structure, they can easily reach a market cap much higher than what they currently have. There are many clinical stage companies with no revenue and market caps $500 million or more. And they didn't lose the DARPA contract. But if you can't be patient take your loss and trade something else. The stock market is a risky place.
I'm paying more attention to market cap than share price. A reverse split is very likely and I would also consider that to be part of "cleaning up the mess." The share price may drop short term but I don't care, I'm not trying to swing trade. I can't predict exactly how much time it will take to get there either, but I see a company that is heading in the right direction.
My thoughts exactly. They are a company that specializes in PIPEs and groups like that are often behind the price manipulation ahead of PIPEs. I see it as another step towards cleaning up the mess and looking more legit. Getting ready for institutional investors and NASDAQ.
Do you see that as good or bad?
The part about the 2nd study in Germany was not clear, but my interpretation was that it was a 2nd study of the filter that was used on the same patient to confirm the count of viruses that were removed. The second study determined 253 million copies removed, compared to the first study which indicated 242 million. A more detailed report by the German doctor would be available next month.
I just listened to the presentation. I didn't hear anything about an RS, however JJ did say that debt was cleared in 2014 in preparation for 2015 uplisting to NASDAQ. He also said that he thinks Wall Street will understand the company better now that they are in more of a clinical trials phase rather than research and development. One can speculate that based on the current share price and number of outstanding shares, a reverse split will be needed to uplist. I think it could work out well in the long run as long as they keep making progress on trials. One of the reasons why reverse splits often don't go well is that they are done by companies already going downhill as a desperation move to avoid delisting. A reverse split combined with an uplisting by an emerging company is a good thing.
I think that the FDA only publishes devices approved for general use. The Hemopurifier is only approved for limited use in clinical trials at this time.
Story today about how Junior Seau's family is fighting the NFL over its inaction on CTE. I think this gives some idea of just how big of a deal it will be if ESI is able to detect CTE in a blood test. I think we are expecting the results of the study with Boston University to be announced within a few weeks. More research will obviously be needed to figure out how to treat CTE, but detection while living is an important start.
sports.yahoo.com/news/on--60-minutes-sports---junior-seau-s-family-explains-why-they-re-still-fighting-nfl-222142045.html
Dengue is especially relevant because it is the next planned non-US trial for the Hemopurifier:
http://ih.advfn.com/p.php?pid=nmona&article=63794507
I'm not a medical expert, but considering the only mention of the HP in this report is in the section on renal failure, I don't think they were looking at viral count in the bloodstream. If they were, the data is completely inconsistent with what Dr. Geiger reported at the ASN conference (400,000 copies per ml of blood down to 1,000 copies per ml of blood). It's odd that Dr. Geiger was completely left out of this report.
Based on the updated info on the clinicaltrials.gov site, this trial will provide more data than just safety. But the downside is that it now shows Dec 2015 as the estimate for results. But I think there are several other possible catalysts that could help the share price between now and then. Results of the NFL CTE study next month could be huge, additional Ebola treatments, new grants, treatments outside the US, approval for additional FDA studies, etc. Ultimately they need FDA approval but the share price could still be much higher than it currently is before they get there.
I like your enthusiasm but the market usually reacts to the results of clinical trials, not the start of them. Patience is needed here.
Merck acquiring CBST for $9.5 billion. Shows you what a developmental stage biotech can potentially be worth.
I think the chances of an acquisition greatly increase after the results of the first FDA trial are in. FDA approval is the biggest risk to the financial success of the product. More trials will be needed before final approval but getting passed the safety trial will do a lot to increase confidence that it will eventually be approved. Negotiations with established medical device companies will likely begin once the FDA gives a thumbs up on product safety.
cbdthchelp... Many of the longs who know a lot more about AEMD than I do seemed to switch over to the stock message board at IV. The tone there is typically more friendly and respectful than it is here. You might want to try asking some questions there.
It's a larger scale HCV study by Medanta Medicity. See http://investorshub.advfn.com/boards/read_msg.aspx?message_id=108085078. The link there has upcoming milestones presented at the investor's conference a few weeks ago.
Hi and welcome to the board. What you are asking is reasonable but it's really a 2 part question. First, the device has already been used once to treat an Ebola patient in Germany. In the U.S., the FDA just recently approved the device for "compassionate use" to treat Ebola patients. Today it was announced that 4 units were shipped to the CDC sponsored biocontainment center in Nebraska, so additional treatments of Ebola patients can happen any time now.
The second part to your question is when can they start making money from the device. I don't think that they can make money (at least not much) from compassionate use. For big profits to happen it has to get through the FDA approved clinical trials. It's hard to say exactly how long that will take. They are just now starting the first trial, which is only intended to demonstrate that the device is safe. I'm guessing (and it's really just a guess) that it will be 2 or 3 months before we hear the results of that. Assuming the results of that trial are good, additional trials will happen next year to evaluate the effectiveness of the device against various conditions. Those trials could take 6 months or a year. It's hard to predict exactly. This is somewhat of a unique situation because the device has been used outside the US so some data is already available, but it still has to go through the FDA protocol. Personally I'm hoping a profitable buyout comes before final FDA approval.
I just read the other news announcement from today... I guess you can add that they are helping to save lives. The company likely needed some funds to manufacture extra devices and filters to send to the containment center without delaying clinical trials.
It is a lot of shares but the good thing is that this is previously issued warrants being exercised, not a new issue. Let the early investors be rewarded. They have and are continuing to help the company grow. It's a good sign that they are showing confidence in the company. In my opinion, it's also a good thing to get those ultra cheap 4 cent options off the books.
I'm pretty sure that was meant to be an estimate for when it would released, not a promise or deadline. It's no big deal if it comes out next week or even the week after. In all honesty, I think the US FDA study that they are just now starting will have a bigger impact on the stock price. The Medicity study is important data, but the FDA saying that the device is safe will do much more to increase confidence that it will eventually be approved for sale.
You are right that is the report from the much smaller trial 2 years ago.
That's the news we've been expecting. Extremely positive. Now it's just a matter of patience until the US FDA trials progress.
I am more concerned about where it will be in 2 to 3 months than where it will go today.
I don't think that this was a fluff PR or old news. The news about the doctor's release was also put out by other sources today:
http://www.newvision.co.ug/news/662188-ebola-ugandan-doctor-reunited-with-family.html
And if you look at Aethlon's facebook page you can see that people have been asking Aethlon about him. I don't think that it is really Aethlon's responsibility to continue providing updates about him, but since they have been asked they put the PR out to pass along the news.
For upcoming catalysts see post 8521 for a summary:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=108085078
The link their is from the presentation at the investor's conference a few weeks ago.
A few of the big ones: Results from the India study should be out any day now. The first US FDA study to demonstrate safety. Results from the NFL Detect CTE study.
They are a developmental stage company that has been issuing shares to raise funds and pay salaries for years. Many of the earlier investors were also given options to buy even cheaper shares, that is well documented in their filings. But all developmental stage companies do that. I think Aethlon probably took longer then they should have to start FDA trials and as a result the number of outstanding shares is now very high. But I don't think that's a reason to be bearish, it only limits the upside potential. The current market cap at this price range is still far below many other developmental stage biotechs and drastically below where it could be when the device is commercialized. They do still have a ways to go before the product is fully approved by the FDA, but if the results from the first trial demonstrate that the product is safe, I think it's likely that a large medical device company will make a buyout offer before final approval. There are risks with every stock but AEMD seems like they are on the right track for major upside over the next few months.
Just saw this article that IBM is also working on technology that can improve solar efficiency:
http://finance.yahoo.com/news/2-innovations-could-transform-solar-132203411.html
Hope Natcore can commercialize their technology quickly. They really only need a small percentage of market share to make the stock worth a lot more than it is today. But if they take too long to get there they will miss their opportunity.
LRAD - 1.46. I bought last week at 1.25 and they have put out 4 press releases in the last 3 days. Earnings announcement next week. Volume is still pretty low, I think it can go up a lot more as it gets more attention.
Anyone looking at LRAD? I bought last week at 1.25 hoping it might go up after next week's earnings. It's now at 1.46 after they put out 4 press releases in 3 days announcing new sales. Volume is still pretty low and I think this one can run higher as it starts to get some attention.
The answer to the dilution question is in the 8-k filed today:
I think the 12,688,650 share count was prior to the reverse split. It was a one-for-five reverse split, so that would bring the share count down to 2,537,730. Their filings also indicate that they have had a share buyback program ongoing for several years now. I don't think they are diluting right now.
DYNT - Dynatronics Corp: NASDAQ traded stock. Outstanding share count is only 2.54M and the float is 1.67M. Yahoo Finance also shows revenue of 30M with a market cap of just 8M. They have an earnings announcement coming up in Feb.
They manufacture and distribute medical and physical therapy equipment. With healthcare reform taking affect and an aging population I think that this is a sector that will see growth. The stock has held up nicely since a reverse split in December.
DYNT - Dynatronics Corp: Here is one that I think is under the radar right now. They manufacture and distribute medical and physical therapy equipment. With healthcare reform taking effect and an aging population I think that this is a sector that will see growth. The stock has held up nicely since a reverse split in December. Outstanding share count is only 2.54M and the float is 1.67M. Yahoo Finance also shows revenue of 30M with a market cap of just 8M. They have an earnings announcement coming up in Feb.
I will keep an eye on SYNM to see how the share price reacts. The fuel has been used in airline flights, Navy ships, and freight trains, so seeing it used it cars does not really provide anything new in my opinion. The event will draw some attention to biofuels but will it really get more people to buy the stock? Basically every time SYNM has put out news in the past year and a half it has caused a short term spike in share price followed by new lows. That is what I expect to happen this time as well. Sorry for being negative on SYNM, those are just my thoughts on this one now.